United States

Septodont's Biodentine and BioRoot Flow Clinical Data Reshape Restorative and Endodontic Protocols in 2026

SHERIDAN, WYOMING - April 10, 2026 - Dental clinicians managing deep cavity restorations and endodontic retreatment decisions now have a richer evidence base to draw from, as Septodont USA's February 2026 clinical newsletter consolidates two-year trial outcomes for BioRoot® Flow and four documented case studies applying Biodentine® in the Bio-Bulk Fill technique for indirect restorations.

Biodentine Bio-Bulk Fill: four clinical cases document deep cavity restoration

Septodont's Case Studies Collection 28 presents workflows from four clinicians who used Biodentine®'s dentine-like mechanical and biological properties to restore deep cavities using the Bio-Bulk Fill technique. The cases extend the application of the material to symptomatic cracked teeth - a notoriously difficult clinical scenario where pulp status is uncertain and cavity geometry is irregular.

AGC Biologics promotes fixed-price 10,000 L microbial GMP slots as Heidelberg capacity expands

Image

SHERIDAN, WYOMING - April 10, 2026 - AGC Biologics has tied an expansion of microbial manufacturing capacity at its Heidelberg facility to a limited-time commercial offer for late-phase and commercial drug developers. The company said it is offering VIP priority slots and set pricing for 10,000 L GMP production, positioning the package as a way to secure supply and reduce exposure to delays. For biopharma companies moving toward launch or scale-up, the development matters because capacity access, price visibility and site selection can materially affect supply planning, regulatory execution and commercial readiness.

AdvaMed Backs USMCA Renewal, Citing Supply Chain Stability and Medtech Export Leadership

SHERIDAN, WYOMING - April 09, 2026 - Medtech supply chains across North America depend on the continued operation of the United States-Mexico-Canada Agreement, and a formal renewal keeps tariff predictability intact for the more than 650 medtech and health tech companies that AdvaMed represents - the majority of them small businesses.

Why USMCA matters to the medtech sector

The U.S. medtech industry spans manufacturing, research and development, and global healthcare delivery. Cross-border supply chains between the United States, Mexico, and Canada underpin both domestic production and the export leadership that U.S. medtech companies hold internationally. Without a stable trilateral trade framework, manufacturers face uncertainty in sourcing components, managing regulatory timelines, and forecasting capital investments.

Senate Reauthorizes SBIR and STTR Programs, Restoring Funding Lifeline for Early-Stage Medtech Startups

SHERIDAN, WYOMING - April 09, 2026 - Federal grant programs that nearly 90 percent of small medtech companies rely on for early-stage R&D funding lapsed on April 09, 2026, and their restoration now hinges on House action following the Senate's passage of reauthorization legislation for the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs.

What the SBIR and STTR programs do

The SBIR and STTR programs distribute competitive grants through 11 federal agencies - including the National Institutes of Health, the National Science Foundation, and the Department of Defense - specifically to small businesses and startups developing early-stage technologies. For medtech, these grants bridge the funding gap between initial concept development and the commercially financeable stages of product development, where venture capital and private equity rarely engage.

AdvaMed urges House action after Senate approves SBIR and STTR reauthorization

WASHINGTON, 4 March 2026: AdvaMed said the U.S. Senate has approved legislation to reauthorize the federal Small Business Innovation Research and Small Business Technology Transfer programs, and the association called on the House of Representatives to move quickly on passage. The medtech trade group said the vote matters because authorization for the two programs lapsed on 30 September 2025, leaving early-stage medical technology companies without the certainty they need as they pursue product research and development.

Amadeus Hospitality Publishes 2026 Football Event Monthly Report as Booking Demand Signals Start Forming

Image

SHERIDAN, WYOMING - April 09, 2026 - Amadeus Hospitality has published the latest edition of its World's Biggest Football Event Monthly Report, timed to the lead-up to the 2026 tournament that begins on June 11. The company positions the report as a planning tool for hoteliers, destination marketing organizations and venues as traveler decisions around timing, destination choice and booking windows begin to take shape. For operators exposed to event-driven demand, the update matters because it frames how early demand signals can be used to target guest mix and revenue opportunities before peak travel patterns fully materialize.

Dentsply Sirona and Siemens Healthineers Achieve FDA Clearance for MAGNETOM Free.Max Dental Edition, the First Dental-Dedicated MRI

Image

SHERIDAN, WYOMING - April 04, 2026 - Dental diagnostic practice faces a structural shift as the first commercially positioned dental-dedicated MRI (ddMRI) clears FDA review, enabling clinicians to visualize soft tissue, nerves, cartilage, and active inflammation without ionizing radiation - capabilities no CBCT or conventional X-ray system can match. The MAGNETOM Free.Max Dental Edition, developed by Dentsply Sirona in collaboration with Siemens Healthineers, now holds FDA clearance following validation in a clinical trial, placing radiation-free soft tissue diagnostics within reach of in-clinic dental settings for the first time.

Perimeter Medical Imaging AI's Claire Earns First FDA PMA for AI-Enabled Breast Cancer Margin Assessment

SHERIDAN, WYOMING - April 03, 2026 - Perimeter Medical Imaging AI has secured FDA premarket approval (PMA) for Claire, making it the first AI-enabled imaging device cleared in the United States for intraoperative breast cancer margin assessment during lumpectomy procedures. Claire, previously marketed as the Perimeter OCT B-Series with ImgAssist AI 2.0, holds FDA Breakthrough Device designation and targets an estimated 300,000 annual U.S. breast-conserving surgeries where residual disease forces re-operations in roughly one in five cases. The approval positions Perimeter to launch a nationwide commercial rollout in the weeks following clearance, converting a clinical trial asset into a revenue-generating platform with expansion potential across additional cancer indications.

Philips Launches Cloud-Enabled IntelliSite Pathology Solution on HealthSuite Powered by AWS

Image

SHERIDAN, WYOMING - April 01, 2026 - Pathology laboratories operating hybrid analog-digital environments face mounting pressure to eliminate on-premise infrastructure bottlenecks as image volumes grow and AI-enabled diagnostics move closer to routine clinical use. Philips' expansion of its digital pathology portfolio with the cloud-enabled Philips IntelliSite Pathology Solution (PIPS) on HealthSuite, powered by Amazon Web Services (AWS), directly addresses this operational gap by removing the requirement for local server infrastructure while enabling secure, remote access to high-resolution whole-slide images across distributed care sites.

What the Senate action changes

SHERIDAN, WYOMING - March 31, 2026 - Early-stage medtech companies could regain a key non-dilutive funding route in 2026 after the Senate passed legislation to reauthorize the federal Small Business Innovation Research and Small Business Technology Transfer programs, reducing uncertainty that has persisted since the programs' authorization lapsed on September 30, 2025. AdvaMed said the Senate action restores momentum for grants that support early research and development at startups and small manufacturers, and it urged the House of Representatives to move quickly on passage. The association framed the programs as an important bridge for companies that struggle to finance next-generation device development before products reach patients or later-stage commercial milestones.